Zoetis presents pipeline with major market approvals expected annually for next several years
Bitget2026/10/27 22:24- Zoetis expects major market approvals every year for the next several years, according to its investor presentation.
- Long-acting Cytopoint is expected in 2026; renal monoclonal antibody therapy is targeted for 2027.
- Oncology monoclonal antibody therapies are expected in 2028-2029; obesity and anxiety treatments are targeted for 2030 onward.
- A focused strategy aims to return Librela to growth in the osteoarthritis pain market.
- The global animal health market is forecast to reach $85 billion-$95 billion by 2035, from about $50 billion in 2024.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Crypto prices
More
